Disulfiram implantation: a dose response trial

Area of Science:

• Addiction Medicine
• Pharmacology
• Clinical Research

Background:

• Alcohol use disorder (AUD) is a chronic relapsing brain condition.
• Disulfiram is an established medication for AUD treatment.
• Subcutaneous implants offer sustained drug delivery for improved adherence.

Purpose of the Study:

• To evaluate the efficacy of different doses of subcutaneous disulfiram implants in maintaining sobriety in individuals with AUD.
• To investigate the relationship between disulfiram implant dosage and treatment outcomes.
• To assess the safety profile, specifically the incidence of disulfiram-ethanol reactions, across different dosage groups.

Main Methods:

• A randomized controlled trial involving 120 alcoholic volunteers.
• Participants received subcutaneous disulfiram implants at three different dosages: 800 mg, 1200 mg, or 1600 mg.
• Patients were followed for a 2-year period to assess sobriety and adverse events.

Main Results:

• All treatment groups demonstrated an increase in sobriety rates post-implantation.
• No statistically significant dose-response relationship was found between disulfiram implant dosage and sobriety.
• There were no significant differences in the occurrence of disulfiram-ethanol reactions among the dosage groups.

Conclusions:

• Subcutaneous disulfiram implants appear to be effective in supporting sobriety in individuals with AUD.
• The dosage of subcutaneous disulfiram implants (800-1600 mg) did not significantly influence sobriety rates or the incidence of adverse reactions.
• Further research may be warranted to optimize disulfiram implant therapy for AUD.